Autopsy report · NCT06405230

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

“Operational challenges”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 6 months before it started.
• Ran for about 9 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Conditions

Lung Cancer, Non-Small Cell

Interventions

Pembrolizumab; Dostarlimab; Pemetrexed+ (carboplatin or cisplatin)

Participants

2

Sites

1

Countries

United Kingdom

Trials that died the same way

• Use of ICON™ to Detect Hemodynamic Variables During Dexmedetomidine Sedation in Children Undergoing Pulmonary Function Test
  “logistical challenges” (67% match in meaning)
• Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions
  “Operational and feasibility constraints due to regulatory requirements” (58% match in meaning)
• Host-microbiota-environment Interactions
  “logistical difficulties” (57% match in meaning)
• Sampling in ARDS Patients Under Inhaled Sedation
  “Logistical issues” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.